Highlights
- CSCs leads to tumor heterogeneity and responsible for recurrence of
treated tumors
- CSCs can be targeted via several signaling pathways
- We discuss preclinical studies on phytocompounds targeted key
regulators of these pathways
- Clinical trials on phytocompounds targeting recurrent cancer are
summarized